News

This week, read about the newest measles update, a clinician's insights on treating the respiratory disease, as well as the latest HIV therapeutic data coming from the CROI conference.

Patricia A Stinchfield, RN, MS, CPNP, discusses her medical experience caring for patients with it, and what fellow clinicians and the general public should know about less-discussed details and potential complications.

The latest CDC numbers show a 15.7% increase of measles cases from week-to-week. This is another large jump in cases, especially from last week where there was a 7.8% increase. The data also shows further outbreak spread across more states.

Eric Meissner, MD, PhD, discusses the takeaways of the ARTISTRY-2, phase 3 study, which compared bictegravir/emtricitabine/tenofovir alafenamide to bictegravir/lenacapavir in adults with HIV who were virologically suppressed.

Phase 1 data show that the long-acting HIV-1 capsid inhibitor VH-499 is well tolerated as a single intramuscular or subcutaneous injection and demonstrates pharmacokinetics supportive of long-acting dosing intervals.

Chloe Orkin, MD, MSc, discusses the takeaways of the ARTISTRY-1 phase 3 study, including its efficacy and safety profile and the potential benefits of a single-tablet regimen in this patient population.

New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analogue AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label options, supporting plans to advance the candidate into phase 1 clinical development in 2026.

Amy Colson, MD, MPH, discusses data from the MK-8591A-052 trial that showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide.

New 96-week subgroup data from the PASO-DOBLE study show that adults with virologically suppressed HIV who switched to dolutegravir/lamivudine experienced significantly lower rates of steatotic liver disease than those who switched to bictegravir/emtricitabine/tenofovir alafenamide, particularly among individuals with clinically meaningful weight gain.

In a phase 3 study of virologically suppressed adults with HIV, switching to once-daily doravirine/islatravir (DOR/ISL 100/0.25 mg) maintained high rates of viral suppression through 96 weeks, with no emergent resistance and a favorable safety profile.

Traws Pharma announced positive phase 2 results showing its investigational COVID-19 antiviral ratutrelvir as a possible alternative to Paxlovid, including for ineligible patients, while advancing tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza.

This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.

The latest CDC numbers show a 7.9% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circulating throughout the US.

In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule.

New phase 3 data show that Merck’s clesrovimab (Enflonsia) maintained a favorable safety profile and supportive pharmacokinetics in high-risk children under 2 years of age during a second RSV season. The company plans to file for expanded regulatory approval.

The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.

Invivyd has aligned with the FDA on the design of a phase 3 trial evaluating the safety and immunology of the company's monoclonal antibody, VYD2311, vs mRNA COVID vaccines and in co-administration.

New real-world evidence presented by GSK shows its RSV vaccine, Arexvy, was associated with substantial reductions in RSV-related hospitalizations and serious cardiovascular and respiratory complications among older adults.

After initially refusing to review Moderna’s investigational mRNA-based seasonal influenza vaccine, the company communicated with the FDA on a revised proposal to seek approval and the federal agency will now review the product. The vaccine's PDUFA decision date is August 5, 2026.

Eric Hall, PhD, MPH, led a modeling study around delaying the universal birth dose for the hepatitis B vaccine, and he offered some insights into potential health care costs when moving away from this dosing.

A newly proposed federal insurance rule for 2027 omits long-promised protections on co-pay assistance, allowing insurers and pharmacy benefit managers to continue diverting billions of dollars intended to help patients afford prescription drugs.

Findings from a real-world population study from Spain show that universal infant immunization with Beyfortus significantly reduced RSV-related hospitalizations not only in the first RSV season but also into the second year of life.

A 6-year study in Liberia shows that Lassa fever is frequently missed in febrile patients, leading to preventable deaths and underscoring the urgent need for earlier diagnosis and improved testing.

This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.

The latest CDC numbers show a nearly 25% increase of measles cases from week-to-week. This marks 2 weeks in a row with a nearly identical increase of cases by percentage, and there are now 5 outbreaks circulating throughout the US.

IDSA’s Amanda Jezek provides the latest update on the legislative bill, including some of its features, its methodology for assigning antimicrobials to the subscription model, and how anyone can advocate for the bill with Congress.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID) describes the potential consequences, including morbidity and mortality rates, if the federal government removed these vaccines.

The Centers for Disease Control and Prevention (CDC) characterizes epidemiology, serotype and treatment resistance of extraintestinal invasive Escherichia coli, the most common pathogen in community-onset sepsis.